Ukrainian Journal of Perinatology and Pediatrics. 2024. 1(97): 22-28. doi: 10.15574/PP.2024.97.22
Romanenko T. G., Yesyp N. V.
Shupyk National Healthcare University of Ukraine, Kyiv

For citation: Romanenko TG, Yesyp NV. (2024). The features of the functioning of the fetoplacental complex in pregnant women with an allogeneic fetus. Ukrainian Journal of Perinatology and Pediatrics. 1(97): 22-28. doi: 10.15574/PP.2024.97.22.
Article received: Dec 24, 2023. Accepted for publication: Mar 12, 2024.

Aim – to determine the features of the functional state of the fetoplacental complex (FPC) in pregnant women with an allogeneic fetus and pregnant women who were involved in assisted reproductive technology (ART) programs using their own oocytes.
Materials and methods. 77 pregnant women were examined. They were divided into two groups: Group I (main) – 39 women who became pregnant as a result of ART using donor oocytes with the formation of an allogeneic fetus; Group II (comparison) – 38 patients who became pregnant as a result of ART using their own oocytes. Statistical processing of research results was carried out using standard Microsoft Excel 5.0 and Statistica 6.0 programs.
Results. Pregnant women with an allogeneic fetus are characterized by significantly lower levels of pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF), determined at 11-13⁺⁶ weeks of pregnancy, and human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) levels, measured at 16-18⁺⁶, compared with a group of women whose own oocytes were used as part of ART programs. In the women of Group I, significantly higher levels of systolic-to-diastolic ratio (SDR) and pulsatility index (PI) of both uterine arteries, resistance index (IR) of the left uterine artery at 20-24 weeks of pregnancy, as well as levels of PI and SDR of the umbilical artery, IR and PI of both uterine arteries and SDR determined for the left uterine artery at 28-31⁺⁶ weeks of pregnancy. In Group I, a significantly lower fetal abdominal circumference was found in comparison to Group II at 28-31⁺⁶ weeks of pregnancy.
Conclusions. The presence of deviations in the indicators of FPC functioning among women of Group I indicates the need for further research of this problem and development of an improved surveillance program for pregnant women with an allogeneic fetus.
The research was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institution indicated in the work. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: assisted reproductive technologies, allogeneic fetus, surrogacy, fetoplacental complex, dopplerometry, fetometry.

REFERENСЕS

1. Akolekar RZ, Poon E, Pepes LC, Nicolaides S. (2008). Maternal serum placental growth factor at 11+0 to 13+6 weeks gestation in the prediction of preeclampsia. Ultrasound Obstetrics Gynecol. 32 (6): 732-739. https://doi.org/10.1002/uog.6244; PMid:18956425

2. Bhide A, Acharya G, Baschat A et al. (2021). ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics. Ultrasound Obstet Gynecol. 58 (2): 331-339. https://doi.org/10.1002/uog.23698; PMid:34278615

3. Blumenfeld YJ, Baer RJ, Druzin ML et al. (2014). Association between maternal characteristics, abnormal serum aneuploidy analytes, and placental abruption. Am J Obstet Gynecol. 211 (2): 144.e1-144.e1449. https://doi.org/10.1016/j.ajog.2014.03.027; PMid:24631707

4. Bouariu A, Panaitescu AM, Nicolaides KH. (2022). First Trimester Prediction of Adverse Pregnancy Outcomes-Identifying Pregnancies at Risk from as Early as 11-13 Weeks. Medicina (Kaunas). 58 (3): 332. Published 2022 Feb 22. https://doi.org/10.3390/medicina58030332; PMid:35334508 PMCid:PMC8951779

5. Dondik Y, Pagidas K, Eklund E, Ngo C, Palomaki GE, Lambert-Messerlian G. (2019). Levels of angiogenic markers in second-trimester maternal serum from in vitro fertilization pregnancies with oocyte donation. Fertil Steril. 112 (6): 1112-1117. https://doi.org/10.1016/j.fertnstert.2019.07.017; PMid:31843087

6. Gagnon A, Wilson RD, Audibert F et al. (2008). Obstetrical complications associated with abnormal maternal serum marker analytes. J Obstet Gynaecol Can. 30 (10): 918-949. https://doi.org/10.1016/S1701-2163(16)32973-5; PMid:19038077

7. Hunt LP, McInerney-Leo AM, Sinnott S et al. (2017). Low first-trimester PAPP-A in IVF (fresh and frozen-thawed) pregnancies, likely due to a biological cause. J Assist Reprod Genet. 34 (10): 1367-1375. https://doi.org/10.1007/s10815-017-0996-1; PMid:28718082 PMCid:PMC5633581

8. Kantomaa T, Vääräsmäki M, Gissler M, Sairanen M, Nevalainen J. (2023). First trimester low maternal serum pregnancy associated plasma protein-A (PAPP-A) as a screening method for adverse pregnancy outcomes. Journal of Perinatal Medicine. 51 (4): 500-509. https://doi.org/10.1515/jpm-2022-0241; PMid:36131518

9. Kojima J, Ono M, Kuji N, Nishi H. (2022). Human Chorionic Villous Differentiation and Placental Development. Int J Mol Sci. 23 (14): 8003. Published 2022 Jul 20. https://doi.org/10.3390/ijms23148003; PMid:35887349 PMCid:PMC9325306

10. Kosińska-Kaczyńska K. (2022). Placental Syndromes-A New Paradigm in Perinatology. Int J Environ Res Public Health. 19 (12): 7392. Published 2022 Jun 16. https://doi.org/10.3390/ijerph19127392; PMid:35742640 PMCid:PMC9224387

11. Krispin E, Kushnir A, Shemer A et al. (2021). Abnormal nuchal translucency followed by normal microarray analysis is associated with placental pathology-related complications. Prenat Diagn. 41 (7): 855-860. https://doi.org/10.1002/pd.5896; PMid:33399234

12. Meroni A, Mascherpa M, Minopoli M et al. (2023). Is mid-gestational uterine artery Doppler still useful in a setting with routine first-trimester pre-eclampsia screening? A cohort study. BJOG. 130 (9): 1128-1134. https://doi.org/10.1111/1471-0528.17441; PMid:36852521

13. Mintser AP. (2018). Statisticheskie metodyi issledovaniya v klinicheskoy meditsine. Prakticheskaya meditsina. 3: 41-45.

14. Ontario Health (Quality). (2022). First-Trimester Screening Program for the Risk of Pre-eclampsia Using a Multiple-Marker Algorithm: A Health Technology Assessment. Ont Health Technol Assess Ser. 22 (5): 1-118. Published 2022 Dec

15. Ortega MA, Fraile-Martínez O, García-Montero C et al. (2022). The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease. Cells. 11 (3): 568. Published 2022 Feb 6. https://doi.org/10.3390/cells11030568; PMid:35159377 PMCid:PMC8833914

16. Papamichail M, Fasoulakis Z, Daskalakis G, Theodora M, Rodolakis A, Antsaklis P. (2022). Importance of Low Pregnancy Associated Plasma Protein-A (PAPP-A) Levels During the First Trimester as a Predicting Factor for Adverse Pregnancy Outcomes: A Prospective Cohort Study of 2636 Pregnant Women. Cureus. 14 (11): e31256. Published 2022 Nov 8. https://doi.org/10.7759/cureus.31256

17. Papageorghiou AT, Yu CKH, Cicero S, Bower S, Nicolaides KH. (2002). Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med. 12 (2): 78-88. https://doi.org/10.1080/713605620

18. Phillips AM, Magann EF, Whittington JR, Whitcombe DD, Sandlin AT. (2019). Surrogacy and Pregnancy. Obstet Gynecol Surv. 74 (9): 539-545. https://doi.org/10.1097/OGX.0000000000000703; PMid:31830299

19. Rizzo G, Mappa I, Bitsadze V et al. (2020). Role of Doppler ultrasound at time of diagnosis of late-onset fetal growth restriction in predicting adverse perinatal outcome: prospective cohort study. Ultrasound Obstet Gynecol. 55 (6): 793-798. https://doi.org/10.1002/uog.20406; PMid:31343783

20. Rolnik DL, Nicolaides KH, Poon LC. (2022). Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 226 (2S): S1108-S1119. https://doi.org/10.1016/j.ajog.2020.08.045; PMid:32835720

21. Söderström-Anttila V, Wennerholm UB, Loft A et al. (2016). Surrogacy: outcomes for surro-gate mothers, children and the resulting families-a systematic review. Human reproduction up-date. 22 (2): 260-276. https://doi.org/10.1093/humupd/dmv046; PMid:26454266

22. Tan MY, Syngelaki A, Poon LC et al. (2018). Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 52 (2): 186-195. https://doi.org/10.1002/uog.19112; PMid:29896812

23. Unterscheider J, Cuzzilla R. (2021). Severe early-onset fetal growth restriction: What do we tell the prospective parents? Prenat Diagn. 41 (11): 1363-1371. https://doi.org/10.1002/pd.6030; PMid:34390005

24. Vollgraff Heidweiller-Schreurs CA, De Boer MA, Heymans MW et al. (2018). Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 51(3): 313-322. https://doi.org/10.1002/uog.18809; PMid:28708272 PMCid:PMC5873403

25. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. (2012). A competing risks model in early screening for preeclampsia [published correction appears in Fetal Diagn Ther. 2013; 34(1):18. Fetal Diagn Ther. 32 (3): 171-178. https://doi.org/10.1159/000338470; PMid:22846473

26. Zhou C, Zou QY, Jiang YZ, Zheng J. (2020). Role of oxygen in fetoplacental endothelial responses: hypoxia, physiological normoxia, or hyperoxia? Am J Physiol Cell Physiol. 318(5): C943-C953. https://doi.org/10.1152/ajpcell.00528.2019; PMid:32267717 PMCid:PMC7294327